Serum myostatin, as a possible biomarker in stroke-related disorders, has been reported for myocardial ischemia-related injury, as a cardiac myostatin upregulation immediately occurs after myocardial ischemia and participates in the ubiquitin-proteasome degradation of proteins, via the atrogin and MuRF1 involvement, in the skeletal muscle [94]. This evidence concerns the gene TRIM63 and myocardial ischemia.